Antivenoms are species- and region-specific, so the available product often fails against the local snake
#00133
Because venom composition varies by species, geography, and age, antivenom raised against one region's snakes frequently fails to neutralize bites elsewhere, and many medically important species have no effective product at all — a scientific matching problem distinct from cost o
#00139Computationally design de novo toxin-neutralizing proteins with deep learning Pending
Use deep-learning protein design (RFdiffusion) to computationally create small, ultra-stable proteins that bind and neutralize conserved venom toxins, manufacturable cheaply by microbial fermentation without animal immunization — as low-cost broad-spectrum antivenom components o…
#00134Deploy repurposed small-molecule toxin inhibitors as broad-spectrum early therapy
Use varespladib (PLA2 inhibitor), marimastat (SVMP inhibitor), and DMPS/dimercaprol (Zn2+ chelators) as cheap, heat-stable, species-agnostic first-line treatment that buys time before or alongside antivenom, particularly in the pre-hospital window.
#00135Use antivenomics to map and license cross-neutralization of existing products against orphan species
Systematically test which existing polyvalent antivenoms already neutralize orphan-species venoms via antivenomics and preclinical assays, then pursue label extensions — expanding effective coverage without developing new products.
#00131Replace animal-derived antivenom with broadly-neutralizing recombinant human antibody cocktails
Manufacture antivenom as a defined cocktail of recombinant human monoclonal antibodies targeting conserved toxin families (3FTx, PLA2, SVMP, SVSP), replacing dozens of narrow regional polyclonal sera with a small number of broad-spectrum products split roughly by neurotoxic-elapi